Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

News release: Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal – University of Oxford

Original study (preprint): High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso – The Lancet

Commentaries: Malaria vaccine hailed as potential breakthrough – BBC AND Oxford Malaria vaccine proves highly effective in Burkina Faso trial – The Guardian

Commentary on Twitter (thread – click for more)

?AMAZING—First high >75% efficacy vaccine for a disease with 229 million cases & 409,000 deaths worldwide in 2019 —#Malaria!

Created by Oxford, produced by Serum Institute of India, & supporting adjuvant by Novavax, SII expects to make 200 mil doses a year!

Science! #vaccine pic.twitter.com/gnPMvXxww6

— Eric Feigl-Ding (@DrEricDing) April 23, 2021